-
BMS, AstraZeneca drug added to insulin reduces blood sugar more than placebo
PRINCETON, N.J. — A diabetes drug made by Bristol-Myers Squibb and AstraZeneca significantly reduced Type 2 diabetes patients' blood-sugar levels, compared with placebo, when added to insulin, according to results of a new study.
The two companies presented results of a 24-week extension to a 52-week study of Onglyza (saxagliptin) at the European Association for the Study of Diabetes' 47th annual meeting in Lisbon, Portugal; they had presented results from the original study at the American Diabetes Association's scientific sessions in San Diego in June.
-
GSK, Amicus start phase-3 trial of Fabry disease drug
CRANBURY, N.J. — GlaxoSmithKline and Amicus Therapeutics have started a late-stage clinical trial for a drug to treat a rare genetic disorder, the companies said.
GSK and Amicus announced the start of a second phase-3 trial of Amigal (migalastat hydrochloride) for Fabry disease, a rare lysosomal storage disorder that affects between 5,000 and 10,000 people worldwide. The market for Fabry disease has long been dominated by Genzyme, a subsidiary of French drug maker Sanofi that makes the biologic drug Fabrazyme (agalsidase beta).